This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Over Active Bladder Patients Having Sling Surgery

This study has been completed.
Astellas Pharma US, Inc.
Information provided by (Responsible Party):
The Cleveland Clinic ( Cleveland Clinic Florida ) Identifier:
First received: February 26, 2009
Last updated: April 18, 2017
Last verified: April 2017
The purpose of this study is to determine whether treatment with anti-muscarinic medications following sub-urethral sling procedures improves overall subjective and objective outcomes in women with mixed incontinence with primary stress symptoms.

Condition Intervention Phase
Overactive Bladder Drug: Solifenacin Other: Placebo Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Participant, Investigator
Primary Purpose: Treatment
Official Title: A Double Blind, Randomized Placebo Controlled Trial of the Perioperative Use of Solifenacin in the Management of Postoperative Overactive Bladder Symptoms in Patients With Mixed Incontinence Undergoing Suburethral Sling Procedures.

Resource links provided by NLM:

Further study details as provided by The Cleveland Clinic ( Cleveland Clinic Florida ):

Primary Outcome Measures:
  • To assess the efficacy of solifenacin in the prevention of postoperative OAB symptoms (urinary frequency,urgency, urge incontinence, nocturia) in women undergoing sub-urethral sling placement for mixed urinary incontinence with primary stress symptoms. [ Time Frame: 11 weeks ]
    Reduction in overactive bladder symptoms

Secondary Outcome Measures:
  • Assess safety of Solifenacin in women having sub-urethral sling procedures, the perioperative period, on quality of life measures on length of hospitalization on the time to resumption of normal voiding in time to removal of suprapubic catheter. [ Time Frame: 11 weeks ]
    reduction in urinary incontinence

Enrollment: 11
Study Start Date: February 2008
Study Completion Date: February 2010
Primary Completion Date: July 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo Group
Placebo Orally 9 weeks once daily.
Other: Placebo
Take orally once daily for 9 weeks.
Experimental: Solifenacin Group
Solifenacin Orally 9 weeks once daily.
Drug: Solifenacin
Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
Other Name: Tolterodine Tartrate

Detailed Description:
Women with mixed incontinence with primary stress symptoms undergoing Sub-Urethral Sling Procedures will be randomized to peri-operative placebo or solifenacin. Subjects in the placebo group will take orally once daily for 9 weeks. Subjects in the Solifenacin group will take orally once daily for 9 weeks.

Ages Eligible for Study:   18 Years to 100 Years   (Adult, Senior)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Age >/= 18
  • Patient is appropriate for sub-urethral sling procedure
  • Mixed urinary incontinence
  • No antimuscarinic therapy for previous 30 days

Exclusion Criteria:

  • Uncontrolled narrow angle glaucoma
  • Acute cystitis
  • Unevaluated hematuria
  • Currently using anti-muscarinic therapy
  • Unable to complete pre-operative urodynamics
  • Contraindication to anti-cholinergic therapy
  • Unable or unwilling to complete diaries or quality of life questionaire
  • Significant (exteriorized) Pelvic Organ Prolapse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852696

United States, Florida
Cleveland Clinic Florida
Weston, Florida, United States, 33331
Sponsors and Collaborators
Cleveland Clinic Florida
Astellas Pharma US, Inc.
Principal Investigator: G W Davila, MD Cleeland Clinic
  More Information

Responsible Party: Cleveland Clinic Florida Identifier: NCT00852696     History of Changes
Other Study ID Numbers: 8867
Study First Received: February 26, 2009
Last Updated: April 18, 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Keywords provided by The Cleveland Clinic ( Cleveland Clinic Florida ):
Overactive Bladder

Additional relevant MeSH terms:
Urinary Bladder, Overactive
Urinary Bladder Diseases
Urologic Diseases
Lower Urinary Tract Symptoms
Urological Manifestations
Signs and Symptoms
Solifenacin Succinate
Tolterodine Tartrate
Muscarinic Antagonists
Cholinergic Antagonists
Cholinergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Physiological Effects of Drugs
Urological Agents processed this record on August 16, 2017